Introduction In Peru, adherence to antihypertensive treatment ranges from 55.5% to 46.6%. Adherence decreases under adverse socioeconomic conditions. Therefore, the aim of this research was to evaluate the socioeconomic inequalities in non-adherence to antihypertensive medication in Peru.

Methods A cross-sectional study was conducted through the analysis of data from the Demographic and Family Health Survey carried out in Peru between 2013 and 2023. We addressed the socioeconomic conditions of hypertensive Peruvian adults, including sex, age group, educational level, area or place of residence, and health insurance. These conditions were evaluated as sources of inequality in non-adherence to antihypertensive medication at a general level using the Concentration Index (CI) or Erreygers’ Correction Index (ECI) among adults over 29 years of age.

Results In the 15,624 hypertensive adults over 29 years old included in the study, the 86.63% had adherence to their antihypertensive medication. However, the inequality in non-adherence to medication was considerable (CI: -0.259; 95%CI: -0.385 to -0.132; p¡0.001). This inequality was greater among those aged 30 to 49 years (CI: -0.064; 95%CI: -0.121 to -0.008; p=0.01-0.2), those living in rural areas (CI: -0.484; 95%CI: -0.537 to -0.430; p¡0.001) or outside the capital (CI: -0.495; 95%CI: -0.569 to -0.422; p¡0.001), and those with no education (CI: -0.156; 95%CI: -0.201 to -0.112; p¡0.001) or only primary education (CI: -0.323; 95%CI: -0.386 to -0.260; p¡0.001). In contrast, hypertensive adults with a university education had a positive CI (CI: 0.257; 95%CI: 0.199 to 0.316; p¡0.001).

Conclussion Hypertensive Peruvian adults residing in rural areas or outside the capital, and those with a low educational level, exhibited greater inequality in adherence to antihypertensive medication.

The authors have declared no competing interest.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The data was obtained from the National Institute of Statistics and Informatics (or INEI, in Spanish) platform: https://proyectos.inei.gob.pe/microdatos/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes